US Court Of Appeals For Federal Circuit Grants ARIAD Petition For Rehearing En Banc
Also vacates its April 2009 decision on Eli Lilly's appeal
ARIAD Pharmaceuticals and its co-plaintiffs have announced that the US Court of Appeals for the Federal Circuit has granted their petition for rehearing en banc, and has vacated its April 2009 decision in the appeal that Eli Lilly filed in 2008.
The company said that all 12 judges of the Federal Circuit will now rehear and reassess the merits of Lilly’s appeal. This decision by the Federal Circuit concerns a judgment holding Lilly liable for infringement of US Patent No. 6,410,516, licensed to ARIAD by Harvard University, Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research.
The company said that in 2006, the jury in the US District Court for the District of Massachusetts ruled unanimously in favor of the plaintiffs. The jury found that the claims of the NF-kB patent asserted in the lawsuit are valid and infringed by Lilly with respect to its osteoporosis drug, Evista and septic shock drug, Xigris.
The company said that jury awarded damages to the plaintiffs based on US sales of these two drugs through the year 2019, when the patent expires. The jury verdict was then upheld in 2007 by Judge Rya Zobel of the District Court.
Related Insight
Suppliers Directory
BaseCon - IT Pharma Solutions
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT solutions by using state-of-the-art technology combined with detailed knowledge of the requirements in the pharmaceutical sector.
Suppliers
Haupt Pharma - Contract Development and Manufacturing, Clinical Trial Supplies, Regulatory Services, Packaging and Logistics
As one of Europe's largest pharmaceutical contract developers and manufacturers Haupt Pharma offers full service, which covers pharmaceutical development, materials procurement, commercial production, packaging and distribution.
Suppliers
David Begg Associates - Pharmaceutical Training, Consultancy and Auditing
Since its foundation in 1986, David Begg Associates (DBA) has risen to become Europe's largest provider of pharmaceutical education and training with an outstanding international reputationin the fields of pharmaceutical quality management and regulatory compliance. DBA now brings that reputation to the US, complementing its EU expertise with experts in FDA and other markets to offer education and training programs, consultancy and auditing services.
Suppliers
Reading Scientific Services Ltd (RSSL) - Customer Driven, Science Led, Results Focused
RSSL is an independent global leader at the forefront of scientific analysis, consultancy, and training, serving the pharmaceutical, healthcare, biopharmaceutical, food, drink and consumer goods industries.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Quality By Design: The Automated Pharmaceutical Assay
Published by Sotax
White Papers
Food
Published by A-Consult
White Papers
HPLC Analysis of lysozyme in different types of wine
Published by Tosoh Bioscience
White Papers
HPLC Analysis of Fluorescently labelled N-Glycans
Published by Ludger
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.